Your browser doesn't support javascript.
loading
Risk of Parkinson's disease dementia related to level I MDS PD-MCI.
Hoogland, Jeroen; Boel, Judith A; de Bie, Rob M A; Schmand, Ben A; Geskus, Ronald B; Dalrymple-Alford, John C; Marras, Connie; Adler, Charles H; Weintraub, Daniel; Junque, Carmen; Pedersen, Kenn F; Mollenhauer, Brit; Goldman, Jennifer G; Tröster, Alexander I; Burn, David J; Litvan, Irene; Geurtsen, Gert J.
Afiliação
  • Hoogland J; Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Boel JA; Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • de Bie RMA; Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands.
  • Schmand BA; Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Geskus RB; Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands.
  • Dalrymple-Alford JC; Department of Medical Psychology, Academic Medical Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Marras C; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Adler CH; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Weintraub D; Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam.
  • Junque C; New Zealand Brain Research Institute, Brain Research New Zealand - Rangahau Roro Aotearoa, Christchurch, New Zealand.
  • Pedersen KF; Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, University of Toronto, Ontario, Canada.
  • Mollenhauer B; Arizona Parkinson's Disease Consortium, Mayo Clinic Arizona, Scottsdale, Arizona, USA, and Banner Sun Health Research Institute, Sun City, Arizona, USA.
  • Goldman JG; Departments of Psychiatry and Neurology, University of Pennsylvania School of Medicine, and Parkinson's Disease and Mental Illness Research, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
  • Tröster AI; Department of Medicine, Faculty of Medicine, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Burn DJ; The Norwegian Centre for Movement Disorders, Department of Neurology, and Memory Clinic, Stavanger University Hospital, Stavanger, Norway.
  • Litvan I; Department of Neurosurgery and Institute of Neuropathology, Paracelsus-Elena-Klinik, Kassel, Germany, and University Medical Center Goettingen, Goettingen, Germany.
  • Geurtsen GJ; Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Rush University Medical Center, Chicago, Illinois, USA.
Mov Disord ; 34(3): 430-435, 2019 03.
Article em En | MEDLINE | ID: mdl-30653248
ABSTRACT

BACKGROUND:

The International Parkinson and Movement Disorders Society criteria for mild cognitive impairment in PD need validation. The objectives of this present study were to evaluate prognostic validity of level I (abbreviated) International Parkinson and Movement Disorders Society mild cognitive impairment in PD criteria for development of PD dementia and compared them with level II (comprehensive) criteria.

METHODS:

We analyzed data from 8 international studies (1045 patients) from our consortium that included baseline data on demographics, motor signs, depression, detailed neuropsychological testing, and longitudinal follow-up for conversion to Parkinson's disease dementia. Survival analysis evaluated their contribution to the hazard of Parkinson's disease dementia.

RESULTS:

Level I mild cognitive impairment in PD, increasing age, male sex, and severity of PD motor signs independently increased the hazard of Parkinson's disease dementia. Level I and level II mild cognitive impairment in PD classification had similar discriminative ability with respect to the time to Parkinson's disease dementia.

CONCLUSIONS:

Level I mild cognitive impairment in PD classification independently contributes to the hazard of Parkinson's disease dementia. This finding supports the prognostic validity of the abbreviated mild cognitive impairment in PD criteria. © 2019 International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Demência / Disfunção Cognitiva Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Demência / Disfunção Cognitiva Idioma: En Ano de publicação: 2019 Tipo de documento: Article